following an abbreviated submission:
patiromer sorbitex calcium (Veltassa®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of hyperkalaemia in adults.
SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia).
Patiromer sorbitex calcium offers an additional treatment choice in the therapeutic class of non-absorbed cation-exchange compounds that act as selective potassium binders.
Download detailed advice728KB (PDF)
- Medicine name:
- patiromer sorbitex calcium (Veltassa)
- SMC ID:
Indicated for the treatment of hyperkalaemia in adults.
- Pharmaceutical company
- Vifor Fresenius Medical Care Renal Pharma UK Ltd
- Submission type
- Date advice published
- 09 August 2021